Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 26.
doi: 10.1097/CEJ.0000000000000982. Online ahead of print.

Impact of HER2 and microsatellite instability status on response to neoadjuvant/conversion therapy and survival in patients with gastric cancer

Stefania Angela Piccioni  1   2 , Maurizio Costantini  3 , Roberto Petrioli  4 , Giulio Bagnacci  2   5 , Domenico Ferrara  3 , Eleonora Andreucci  1   2 , Ludovico Carbone  1   2 , Alessandra Ongaro  6 , Natale Calomino  7 , Marta Sandini  1   2 , Maria Antonietta Mazzei  2   5 , Franco Roviello  1   2 , Daniele Marrelli  1   2
Affiliations

Impact of HER2 and microsatellite instability status on response to neoadjuvant/conversion therapy and survival in patients with gastric cancer

Stefania Angela Piccioni et al. Eur J Cancer Prev. .

Abstract

Objectives: The prognostic significance of microsatellite instability (MSI) and HER2 status in advanced gastric cancer (AGC) treated with neoadjuvant or conversion chemotherapy (NAC) remains unclear. This study aimed to evaluate their impact on pathological response and survival outcomes in AGC patients undergoing NAC followed by surgery.

Methods: This single-center, retrospective observational study included 121 patients with gastric adenocarcinoma at clinical stage >cT2N0, defined as tumor invasion beyond the muscularis propria, nodal involvement, or both. Eligible patients received at least two cycles of NAC and underwent surgical resection. Adults without other malignancies and with biopsy samples available for molecular analysis were included. Data were obtained from a prospectively maintained surgical database. Imaging studies were reviewed by expert radiologists, and molecular analyses were performed in the pathology department.

Results: Among the 121 patients, MSI was identified in 6.6% and HER2 positivity in 9.9%. All MSI tumors were HER2 negative (P < 0.001). HER2 positivity was more frequent in intestinal-type tumors (P = 0.034) and was associated with better pathological response (P = 0.048). The 5-year overall survival (OS) rate was 44.7%, with a median OS of 42.6 months. Multivariate Cox regression identified tumor location in the upper third, residual tumor, nodal stage, Lauren diffuse-mixed histotype, and negative HER2 status as independent prognostic factors (P < 0.05). MSI status was not significantly associated with OS (P = 0.786), although a trend toward improved survival was observed in MSI-H patients.

Conclusions: HER2 overexpression correlated with better pathological response and independently predicted improved OS. MSI and HER2 status may serve as biomarkers to guide preoperative treatment strategies in AGC.

Keywords: gastric cancer; human epidermal growth factor receptor 2; microsatellite instability; neoadjuvant; survival.

PubMed Disclaimer

References

    1. Abrahao-Machado LF, Scapulatempo-Neto C (2016). HER2 testing in gastric cancer: an update. World J Gastroenterol 22:4619–4625.
    1. Al-Batran S-E, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al.; FLOT4-AIO Investigators (2019). Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction denocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet (London, England) 393:1948–1957.
    1. Al-Batran S-E, Haag GM, Ettrich TJ, Borchert K, Kretzschmar A, Teschendorf C, et al. (2020). 1421MO Final results and subgroup analysis of the PETRARCA randomized phase II AIO trial: perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2 positive resectable esophagogastric adenocarcinoma. Ann Oncol 31:S899.
    1. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al.; ToGA Trial Investigators (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687–697.
    1. Bass AJ, Thorsson V, Shmulevich I, Reynolds SM, Miller M, Bernard B, et al. 2014a). Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513:202–209.

LinkOut - more resources